Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

David-Alexandre C. Gros, Chief Executive Officer of Eledon Pharmaceuticals

“The patient-reported outcomes presented at ASN Kidney Week provide perhaps the clearest picture yet of what tegoprubart’s differentiated profile means for transplant patients in everyday life.”

David-Alexandre C. Gros, Chief Executive Officer of Eledon Pharmaceuticals

“We previously reported encouraging BESTOW results across efficacy, kidney function and safety measures, which alone strengthened our belief in tegoprubart.”

David-Alexandre C. Gros, Chief Executive Officer of Eledon Pharmaceuticals

“The additional findings presented demonstrate that these clinical outcomes were accompanied by substantial and importantly sustained improvements in quality of life and reductions in transplant-related symptom burden.”

David-Alexandre C. Gros, Chief Executive Officer of Eledon Pharmaceuticals

“Giving transplant patients an effective, safer and more tolerable alternative to tacrolimus addresses one of the most important unmet needs in organ transplantation, and collectively, these data further support the potential of tegoprubart to become a transformative new treatment option for kidney transplant recipients.”

Andrew Adams, Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota

“Success after kidney transplantation is measured not only by preventing rejection and preserving graft function, but also by how patients feel and function in their everyday lives.”

Andrew Adams, Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota

“What is particularly compelling about these BESTOW results is the consistency of the patient-reported benefits when treated with tegoprubart compared with tacrolimus following kidney transplant.”

Andrew Adams, Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota

“We observed broad improvements in quality-of-life measures together with remarkably favorable outcomes in transplant-specific symptom reporting.”

Andrew Adams, Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota

“The extent of separation between treatment groups suggests patients receiving tegoprubart may experience meaningful quality of life advantages while maintaining strong clinical outcomes as previously reported from BESTOW.”